Yes, I will add caution by saying that we are seeing that many more of the applications that come to Health Canada are for orphan indications.
Relating to the question on genetic testing, as Dr. Stewart said, we're seeing a lot of medications coming through where as a result of genetic work, they are able to identify a subset of a disease. The disease itself may not be orphaned, but the subset is orphaned. We're seeing much more of that, so when we talk about what we're doing for all drugs, we are seeing a large proportion of orphan drugs.
One of the concerns we had going forward with specific regulations was that you have to tie them to a specific definition. Most definitions are based on incidents. For example—